Monoclonal Antibody Ligands for Liposomes Functionalization: Immunoliposomes Formulation and Clinical Status

Abstract

The targeted liposomes prepared with mAbs or their fragments are known as immunoliposomes. The mechanism of action explained for mAb is also applicable to targeted liposomes, but with the advantage that a single targeted liposome can bind to multiple receptors at the same time. However, it has been described that one of the main problems associated with the polyethylene glycol (PEG) layer is related to liposome-cell interaction, because of PEG may interfere in the cell recognition, uptake of the liposomes. However, targeted liposomes show important differences regarding the PK behavior in comparison with non-targeted, which require to be commented in this section. In these healthy mice, no differences between targeted and non-targeted liposomes have often established. In preclinical assays, this formulation has shown a tumor cell interaction and uptake higher than non-targeted liposomes. In order to solve this problem, a new strategy consisting in the conjugation of several types of ligands on the surface of liposomes, provides the multi-targeting liposomes.